Pharmaceutical intermediate Gentamycin Sulfate Powder 1405-41-0

CAS:1405-41-0

MF: C60H127N15O26S

MW:1506.8

EINECS:215-778-9

Specification: 99% min Gentamycin Sulfate Powder

Sample: Gentamycin Sulfate Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Gentamycin Sulfate Powder Usage and Synthesis.

Gentamicin Sulfate is a glycoside bactericidal antibiotic linked by aminosugar and ligand, the sulfate of gentamicin, with an antibacterial spectrum similar to that of kanamycin.

It is mainly used for systemic or local infections caused by gram-negative bacteria such as Escherichia coli, dysentery bacillus, Klebsiella pneumoniae, Proteus mirabilis and Pseudomonas aeruginosa. Ophthalmology is used for conjunctivitis and keratitis.

Oral can be used for intestinal infections or preparation for colon surgery; can also be used in combination with metronidazole or clindamycin to reduce the rate of infection in colon surgery.

Uses of Gentamycin Sulfate.

Gentamicin blocks the transfer of peptidyl-tRNA from the acceptor site to the donor site by binding to the 30S ribosomal subunit and causing a codon misreading.

The bactericidal effect of gentamicin against Pseudomonas aeruginosa relies on binding to the outer membrane portion of the cell membrane, displacing the cations that would otherwise be present, destabilising the membrane, and forming cavities on the cell surface.

Antibacterial spectrum: Gram-negative bacteria, staphylococci and other Gram-positive bacteria.

Clinically used for septicaemia, respiratory tract infections, biliary tract infections, purulent peritonitis, intracranial infections, urinary tract infections and bacillary dysentery caused by Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, dysentery bacillus, Klebsiella, Proteus mirabilis and other sensitive bacteria.

Physiological Effects of Gentamycin Sulfate.

Gentamicin sulphate is an aminoglycoside drug that acts on the ribosome in bacteria, inhibiting bacterial protein synthesis and disrupting the integrity of the bacterial cell membrane to exert bactericidal action.

The drug can first pass through the pore proteins of the extracellular membrane by passive diffusion, and then enter the cell through the cell membrane by the transporter system, and irreversibly bind to the 30s subunit of the isolated ribosome, resulting in the disruption of the A-site, which in turn:

(1) preventing the correct localisation of aminoacyl tRNAs at the A-site, particularly hindering the binding of methionyl tRNAs, thereby interfering with the assembly of functional ribosomes and inhibiting the formation of the 70s initiation complex.

(2) Induces a mismatch between tRNA and mRNA codon triplets, causing misreading of the genetic code of the 30s subunit of the intact ribosome, resulting in the insertion of incorrect amino acids into the protein structure, leading to abnormal, non-functional protein synthesis.

(3) Hinders the binding of the termination factor to the A site, preventing the release of the synthesised peptide chain and preventing the dissociation of the 70s intact ribosome. (4) Hinders the process of polyribosome depolymerisation and assembly, resulting in ribosome depletion in bacteria.

Drug interactions of  Bulk Gentamycin Sulfate Powder.

(1) Combination with other aminoglycosides or sequential consecutive local or systemic application may increase their production of ototoxicity, nephrotoxicity and neuromuscular blocking effects.

(2) Combined with neuromuscular blocking drugs, it may aggravate the neuromuscular blocking effect, resulting in muscle weakness, respiratory depression and other symptoms.

(3)Combination with colistin, cisplatin, etanercept, furosemide, vancomycin, desmethyl vancomycin, etc., or successive consecutive local or systemic applications, may increase ototoxicity and nephrotoxicity.

(4) Gentamicin sulphate may increase nephrotoxicity when used in combination with cefotiophene and cefazolin topically or systemically.

(5)Combination with polymyxin-like injections or successive local or systemic applications may increase nephrotoxicity and neuromuscular blockade.

(6) Gentamicin sulphate should not be combined with other nephrotoxic and ototoxic drugs or successive consecutive applications, so as not to aggravate nephrotoxicity or ototoxicity.